VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
VRDNViridian Therapeutics, Inc.
$30.06$2.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
VRDN logo

Viridian Therapeutics, Inc.

VRDN
NASDAQ · Immunology Biotech
$30.06
At close - Nov 17, 4:00 PM EST - USD
Market Cap$2.71B
P/E-7.5x
52W High$34.29
Volume1.81M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Milestone-Driven Revenue Masks Persistent Cash Burn Risk

Viridian's fundamentals are defined by lumpy, milestone-timed revenue that swung from $70.6M in 2025Q3 to $25.8M in 2026Q3 against a backdrop of operating losses between roughly $100M and $125M per quarter, suggesting the business remains a pre-commercial clinical platform rather than a self-funding enterprise.

GrowthMixed
ProfitabilityWeak
ValuationReview
TechnicalsStrong
Explore valuation models
MARKET ACTION

VRDN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

-119% Peers

P/E is 119% below peer median

03

Market leadership

RS 89 · Leader

High momentum (Outperforming 89% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 4

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
VRDN-2.02%
S&P 500 (^GSPC)+7.21%
1-Year Return
VRDN+3.66%
S&P 500 (^GSPC)+10.03%
3-Year Return
VRDN+89.29%
S&P 500 (^GSPC)+56.52%
5-Year Return
VRDN+58.21%
S&P 500 (^GSPC)+55.99%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-7.5x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-7.5x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$1.59-94.7%
Base (Fair)$27.77-10.0%
Bull$1.54-94.9%
$1.59 Bear$27.77 Base$1.54 Bull
Current Market Price: $30.06
Trades at a 8.2% premium to Base DCF ($27.77)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$71M+23359.9% YoY
Net income FY25
-$343M-26.9% YoY
Free cash flow FY25
-$277M-18.9% YoY
Operating margin FY25
-512.9%+98505.3 pts YoY
ROIC (FY25)-47.3%
Avg ROIC 5Y-52.6%
ROE (TTM)-69.8%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (50%)
Revenue Beat Rate8/12 (73%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 4, 2026
-$0.81+20.6%
vs -$1.02
$26M+445.1%
vs $5M
Q3 2026
Aug 6, 2026
-$1.05-1.9%
vs -$1.03
$284,000+403.9%
vs $56,364
Q2 2026
May 5, 2026
-$0.90+15.1%
vs -$1.06
$141,000+290.8%
vs $36,083
Q1 2026
Feb 26, 2026
-$1.08-20.0%
vs -$0.90
$132,000-99.3%
vs $18M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Nov 9, 2026
Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans Transcript

Viridian Therapeutics, Inc. ( VRDN ) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans November 9, 2026 8:00 AM EST Company Participants Greg Rossino Stephen Mahoney - CEO, President & Director Radhika Tripuraneni - Chief Medical Officer Shan Wu - Chief Business Officer Conference Call Participants Faisal Khurshid - Jefferies LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Thomas Smith - Leerink Partners LLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Joseph Thome - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Dina Elmonshed - UBS Investment Bank, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Anish Nikhanj - Truist Securities, Inc., Research Division Qiu Wu - Goldman Sachs Group, Inc., Research Division John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics Conference Call.

Benzinga·Nov 9, 2026
Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing

Viridian Therapeutics Inc. (NASDAQ:VRDN) reported positive Phase 1 clinical trial results for VRDN-008, highlighting its pharmacokinetic and pharmacodynamic profile as a potential best-in-class subcutaneous treatment for autoimmune and rare diseases.

Business Wire·Nov 9, 2026
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008. “Today's VRDN-008 data exceeded expectations and demonstrates a potentially transformative FcRn-inhibitor profile. Based on these data, we believe VRDN-008 dosed subcutaneously every 8 weeks can deliver deep and sustain.

Business Wire·Nov 6, 2026
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1 clinical trial in healthy volunteers and development plans for its neonatal Fc receptor (FcRn) portfolio on Monday, November 9, 2026, at 8:00 a.m. ET. Conference Call and.

Filtered for Viridian Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark VRDN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Viridian Therapeutics, Inc. (VRDN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
VRDN logoVRDNViridian Therapeutics, Inc.Current
$30.06$2.71B-7.5223359.93%-1724.06%-69.76%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
RDVT logoRDVTRed Violet, Inc.
$69.37$978.74M62.0720.03%16.98%12.93%0.42%
KYMR logoKYMRKymera Therapeutics, Inc.
$121.52$10B-34.81-16.72%-341.87%-22.39%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.06$8.5B-24.77-100%—-29.41%—
AMGN logoAMGNAmgen Inc.
$457.93$247.15B26.629.92%24.12%85.59%2.06%

Compare VRDN vs Peers

Viridian Therapeutics, Inc. (VRDN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for VRDN.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare VRDN against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, RDVT, KYMR, PRAX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

VRDN SEC Filings & Documents

Viridian Therapeutics, Inc. (VRDN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 4, 2026·SEC

Material company update

Aug 6, 2026·SEC

Material company update

Jun 29, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Mar 3, 2025·SEC

FY 2024

Feb 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 4, 2026·SEC

FY 2026

Aug 6, 2026·SEC

FY 2026

May 5, 2026·SEC

Get notified when VRDN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

VRDN Frequently Asked Questions

Viridian Therapeutics, Inc. (VRDN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Viridian Therapeutics, Inc.'s revenue?

Viridian Therapeutics, Inc. (VRDN) reported $26.3M in revenue over the trailing twelve months. Revenue was $70.8M in fiscal year 2025. That is 1508% more than the $4.4M of fiscal year 2012.

How fast is Viridian Therapeutics, Inc. growing?

Viridian Therapeutics, Inc. (VRDN) revenue fell by 62.8% over the trailing twelve months, compared with the twelve months before.

Is VRDN profitable?

No. Viridian Therapeutics, Inc. (VRDN) reported a net loss of $453.6M over the trailing twelve months.

Dividend & Returns
What is VRDN's return on equity?

Viridian Therapeutics, Inc. (VRDN) had a return on equity (ROE) of -69.8% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Viridian Therapeutics, Inc.'s free cash flow?

Viridian Therapeutics, Inc. (VRDN) had negative free cash flow of $343.4M over the trailing twelve months.

What if you invested $1,000 in VRDN back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →